Mantle Cell Lymphoma

Cyclin D1-overexpressing B-cell NHL — CCND1/IGH translocation, blastoid variant, BTK inhibitor revolution, and MRD-guided consolidation strategies

Key Points

• Mantle cell lymphoma (MCL) is an aggressive B-cell NHL defined by the t(11;14)(q13;q32) translocation, driving cyclin D1 overexpression and uncontrolled cell cycle progression.
• MCL comprises ~6% of all NHL, with a median age at diagnosis of ~68 years and a strong male predominance (3:1 male:female).
• Classic MCL presents with widespread nodal disease, splenomegaly, bone marrow involvement, and often peripheral blood involvement (leukemic phase).
• Blastoid and pleomorphic variants are highly aggressive, with TP53 mutations conferring particularly poor prognosis and resistance to standard therapy.
• The BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib have transformed relapsed/refractory MCL, achieving durable responses with high tolerability.
• Frontline intensive therapy (R-CHOP/R-DHAP alternating or Nordic regimen) followed by ASCT consolidation is the standard for younger fit patients.
• Brexucabtagene autoleucel (KTE-X19) is FDA approved for relapsed/refractory MCL after BTK inhibitor failure, representing the first CAR-T approval in MCL.

Epidemiology & Incidence

Mantle cell lymphoma accounts for approximately 6% of all non-Hodgkin lymphomas in Western countries, with ~4,500 new cases annually in the United States. The median age at diagnosis is 68 years, and the disease is substantially more common in men (3:1 male:female ratio). MCL is rare in patients under 40. Historically considered incurable with conventional chemotherapy, MCL has a median overall survival of approximately 5–7 years in the modern era. Survival is highly heterogeneous — a subset of indolent leukemic non-nodal MCL (SOX11-negative, mutated IGHV) has a more indolent course…

Molecular Biology & Pathology

The hallmark molecular event in MCL is the t(11;14)(q13;q32) translocation, present in >95% of cases, which juxtaposes the CCND1 (cyclin D1) gene on chromosome 11q13 to the immunoglobulin heavy chain (IGH) enhancer on 14q32. This leads to cyclin D1 overexpression, accelerating G1-to-S cell cycle transition and driving uncontrolled proliferation. Cyclin D1 IHC staining and FISH for t(11;14) are the diagnostic gold standards. In the rare cyclin D1-negative MCL (~5%), cyclin D2 or D3 overexpression driven by t(2;12) or t(6;14) substitutes; SOX11 IHC is positive in both cyclin D1-positive and…

Clinical Presentation

MCL is typically diagnosed at an advanced stage. Over 70% of patients have stage IV disease at presentation, with bone marrow and peripheral blood involvement common. Common presenting features: • Painless lymphadenopathy: Peripheral and central adenopathy is universal in nodal MCL; cervical, axillary, and inguinal nodes are most commonly involved. • Splenomegaly: Present in ~50–80%; can be massive; causes left upper quadrant fullness, early satiety, and pain. • B symptoms (fever, drenching night sweats, ≥10% weight loss): Present in ~30–50%; more common in blastoid variant. • Peripheral…

Diagnosis, Staging & Risk Stratification

Diagnosis: Excisional lymph node biopsy (preferred) or bone marrow biopsy if nodal tissue is not accessible. Core needle biopsy is acceptable in select cases. Required studies: • Morphology: Monotonous small-to-medium lymphocytes with irregular nuclear contours; blastoid variant resembles lymphoblastic lymphoma. • IHC: CD20+, CD5+, CD23−/low, FMC7+, cyclin D1+, SOX11+ (for classic MCL); Ki-67 (proliferation index — critical for prognosis; >30% is high risk). • FISH: t(11;14) confirmation • Flow cytometry: CD5+/CD19+/CD20+/CD23−/FMC7+/kappa or lambda light chain restriction • Peripheral blood…

Treatment

Management is stratified by age/fitness and biologic risk. There is no established curative therapy for most patients. Young/fit patients (typically <65–70, ECOG PS 0–2): • Intensive induction: Alternating R-CHOP/R-DHAP (rituximab + CHOP alternating with rituximab + dexamethasone + high-dose cytarabine + cisplatin) — the European MCL Network MCL Younger trial demonstrated superior outcomes with cytarabine-containing regimens over R-CHOP alone. • Nordic regimen: Dose-intensified rituximab-maxi-CHOP alternating with R-high-dose-AraC. • Consolidation: Autologous stem cell transplantation (ASCT)…